Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : 2026 TeoTwawKi ... 2032 Darkest Interregnum -- Ignore unavailable to you. Want to Upgrade?

To: TobagoJack who wrote (163414)	8/6/2021 6:44:08 AM
From: THE ANT	Read Replies (1) \| Respond to of 218704

SRPT back in the drivers seat to create the first Duchene's Musculature Dystrophy treatment. Their Stage III viral gene treatment for DMD starts in September (only competitor is Pfizer whose treatment is more dangerous, less effective, and behind) Their stage III PPMO trial to start this year(No competitors). They will eventually have hundreds of gene treatment medications from the PPMOs. Their PMOs treat COVID but no one wants a treatment yet. They have 1.7 billion in cash with 5.4 billion market cap and 600 million in sales probably topping at 800 million on the 3 drugs already approved